Robert L. Coleman, MD, FACOG, FACS

Articles

Dr. Coleman on the Potential of Tisotumab Vedotin in Cervical Cancer

January 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

January 18th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Dr. Coleman on Recent Advances and Remaining Questions in Ovarian Cancer

May 5th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Dr. Coleman on Recent Advancements Made in Cervical Cancer Treatment

May 2nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Dr. Coleman on Results of the VELIA Trial in Ovarian Cancer

March 12th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.

Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice

March 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.

Dr. Coleman on the Safety Profile of Veliparib in Ovarian Cancer

February 22nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the safety profile of veliparib examined in the VELIA trial looking at patients with high-grade serous ovarian cancer.

Dr. Coleman on the Use of Veliparib in Ovarian Cancer

January 29th 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

Dr. Coleman on Implications of the VELIA Trial in Ovarian Cancer

January 21st 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the implications of the phase III VELIA trial in ovarian cancer.

Dr. Coleman on Ongoing Research in Cervical Cancer

November 14th 2019

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Dr. Coleman on Investigational Treatment Strategies in Cervical Cancer

November 8th 2019

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses investigational treatment strategies in cervical cancer.

Dr. Coleman on Rationale for Using Veliparib and Chemotherapy in Ovarian Cancer

October 15th 2019

Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.

Dr. Coleman on the Use of Immunotherapy in Cervical Cancer

October 10th 2019

Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.

Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer

March 28th 2019

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of rucaparib in the treatment of patients with ovarian cancer.

Dr. Coleman on the Effect of Age on Rucaparib Efficacy in Ovarian Cancer

March 17th 2019

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the effect of age on the efficacy of rucaparib (Rubraca) in patients with recurrent ovarian carcinoma.